| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442636 | European Journal of Cancer | 2015 | 11 Pages |
Abstract
Twice weekly subcutaneous applications of MGN1703 in a dose of up to 60Â mg are safe and well tolerated without dose-limiting toxicities. MGN1703 shows immune activation and anti-tumour efficacy in heavily pretreated patients. The recommended dose of 60Â mg twice weekly is currently used in a phase II trial in small cell lung cancer and a phase III trial in colorectal cancer patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Martin R. Weihrauch, Heike Richly, Michael S. von Bergwelt-Baildon, Hans Jiro Becker, Manuel Schmidt, Ulrich T. Hacker, Alexander Shimabukuro-Vornhagen, Udo Holtick, Bahar Nokay, Matthias Schroff, Burghardt Wittig, Max E. Scheulen,